Lumos Pharma, Inc. (NASDAQ:LUMO) Q3 2023 Earnings Conference Call November 8, 2023 8:30 AM ET

Company Participants

Lisa Miller - Senior Director, IR

Rick Hawkins - CEO and Chairman

John McKew - President and CSO

Duke Pitukcheewanont - SVP, Global Clinical Development and Medical Affairs

Lori Lawley - CFO

Conference Call Participants

Charles Duncan - Cantor Fitzgerald

Yasmeen Rahimi - Piper Sandler

Leland Gershell - Oppenheimer

Ed White - H.C. Wainwright

Catherine Novack - Jones Trading

Operator

Good morning and welcome to Lumos Pharma's Topline Results Conference Call. Currently, all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time. As a reminder, this conference call is being recorded.

I will now turn the call over to Lisa Miller, Senior Director of Investor Relations.

Lisa Miller

Thank you, operator. Before we proceed with the call, I would like to remind everyone that certain statements made during this call are forward-looking statements under US Federal Securities laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations.

Additional information concerning factors that could cause actual results to differ is contained in our periodic reports filed with the SEC. The forward-looking statements made during this call speak only as of the date hereof and the company undertakes no obligation to update or revise the forward-looking statements.

Information presented on this call is contained in the press release we issued yesterday and in our Form 8-K, which may be accessed from the Investors page of the company's website.

Speaking on today's call will be Rick Hawkins, CEO and Chairman; John McKew, our President and Chief Scientific Officer; Dr. Duke Pitukcheewanont, Senior Vice President of Global Clinical and Medical Affairs; and Lori Lawley, Chief Financial Officer.

I will now turn the call over to Rick.

Rick Hawkins

Thank you, Lisa and good morning everyone. After the market closed yesterday, we issued a press release announcing topline results from our Phase 2 OraGrowtH210 and OraGrowtH212 trials of oral LUM-201 in Pediatric Growth Hormone Deficiency or PGHD.

I'm pleased to report that all primary and secondary endpoints were met in both trials and data from these trials provide supportive evidence--

[Technical Difficulty]

Operator

Ladies and gentlemen, thank you for standing by. We apologize for the technical difficulty. We will now return to the conference. Please go ahead.